Isolevuglandins covalently modify phosphatidylethanolamines in vivo: Detection and quantitative analysis of hydroxylactam adducts

Free Radical Biology and Medicine

Volumn 47, Issue 11, 2009, Pages 1539-1552

  Li, Wei ^a   Laird, James M ^a   Lu, Liang ^a   Roychowdhury, Sanjoy ^b   Nagy, Laura E ^a,b   Zhou, Rong ^a   Crabb, John W ^a,b   Salomon, Robert G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biomarker; Free radical; Isoketal; Isolevuglandin; Levuglandin; Mass spectrometry; Oxidative stress; Phosphatidylethanolamine; Protein adduct

Indexed keywords

HYDROXYLACTAM; ISOLEVUGLANDIN; LACTAM; LEVUGLANDIN; PHOSPHATIDYLETHANOLAMINE; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DOSIMETRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VIVO STUDY; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; QUANTITATIVE ANALYSIS; RETINA MACULA DEGENERATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ANALYSIS;

ANIMALS; ARACHIDONIC ACIDS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY, CHRONIC; ETHANOL; HUMANS; LACTAMS; MACULAR DEGENERATION; MASS SPECTROMETRY; MICE; OXIDATIVE STRESS; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPASES A2; PROSTAGLANDINS E;

MUS;

EID: 70350620704     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.09.003     Document Type: Article

References (59)

1. 2 and a novel intramolecular 1,2-hydride shift during endoperoxide fragmentation in aqueous solution. J. Am. Chem. Soc. 106 (1984) 6049-6060
2. Salomon R.G., and Miller D.B. Levuglandins: isolation, characterization, and total synthesis of new secoprostanoid products from prostaglandin endoperoxides. Adv. Prostaglandin Thromboxane Leukotriene Res. 15 (1985) 323-326
3. Salomon R.G., Subbanagounder G., Singh U., O'Neil J., and Hoff H.F. Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem. Res. Toxicol. 10 (1997) 750-759
4. Brame C.J., Salomon R.G., Morrow J.D., and Roberts II L.J. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem. 274 (1999) 13139-13146
5. Salomon R.G. Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways. Chem. Phys. Lipids 134 (2005) 1-20
6. Bernoud-Hubac N., Davies S.S., Boutaud O., Montine T.J., and Roberts II L.J. Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway. J. Biol. Chem. 276 (2001) 30964-30970
7. 2 with proteins. Prostaglandins 34 (1987) 643-656
8. 2 via the levuglandin pathway. Biochemistry 38 (1999) 9389-9396
9. Amarnath V., Valentine W.M., Amarnath K., Eng M.A., and Graham D.G. The mechanism of nucleophilic substitution of alkylpyrroles in the presence of oxygen. Chem. Res. Toxicol. 7 (1994) 56-61
10. Roberts II L.J., Salomon R.G., Morrow J.D., and Brame C.J. New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. FASEB J. 13 (1999) 1157-1168
11. 2. J. Org. Chem. 59 (1994) 6044-6050
12. 2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J. Biol. Chem. 274 (1999) 20271-20280
13. 2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro. Chem. Res. Toxicol. 17 (2004) 613-622
14. 2-protein adducts in human plasma and vasculature. Chem. Res. Toxicol. 10 (1997) 536-545
15. Salomon R.G., Batyreva E., Kaur K., Sprecher D.L., Schreiber M.J., Crabb J.W., Penn M.S., DiCorletoe A.M., Hazen S.L., and Podrez E.A. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim. Biophys. Acta 1485 (2000) 225-235
16. Brame C.J., Boutaud O., Davies S.S., Yang T., Oates J.A., Roden D., and Roberts II L.J. Modification of proteins by isoketal-containing oxidized phospholipids. J. Biol. Chem. 279 (2004) 13447-13451
17. Salomon R.G., Kaur K., and Batyreva E. Isolevuglandin-protein adducts in oxidized low density lipoprotein and human plasma: a strong connection with cardiovascular disease. Trends Cardiovasc. Med. 10 (2000) 53-59
18. Evans T.A., Siedlak S.L., Lu L., Fu X., Wang Z., McGinnis W.R., Fakhoury E., Castellani R.J., Hazen S.L., Walsh W.J., Lewis A.T., Salomon R.G., Smith M.A., Perry G., and Zhu X. The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Am. J. Biotech. Biochem. 4 (2008) 61-72
19. Govindarajan B., Laird J., Salomon R.G., and Bhattacharya S.K. Isolevuglandin-modified proteins, including elevated levels of inactive calpain-1, accumulate in glaucomatous trabecular meshwork. Biochemistry 47 (2008) 817-825
20. Salomon R.G. Levuglandins and isolevuglandins: stealthy toxins of oxidative injury. Antioxid. Redox Signaling 7 (2005) 185-201
21. Salomon R.G. Isolevuglandins, oxidatively truncated phospholipids, and atherosclerosis. Ann. N. Y. Acad. Sci. 1043 (2005) 327-342
22. 2. Biochemistry 32 (1993) 4090-4097
23. 2 inhibits mitosis and microtubule assembly. Prostaglandins 39 (1990) 611-622
24. Guichardant M., Taibi-Tronche P., Fay L.B., and Lagarde M. Covalent modifications of aminophospholipids by 4-hydroxynonenal. Free Radic. Biol. Med. 25 (1998) 1049-1056
25. Zemski Berry K.A., and Murphy R.C. Characterization of acrolein-glycerophosphoethanolamine lipid adducts using electrospray mass spectrometry. Chem. Res. Toxicol. 20 (2007) 1342-1351
26. Bernoud-Hubac N., Fay L.B., Armarnath V., Guichardant M., Bacot S., Davies S.S., Roberts II L.J., and Lagarde M. Covalent binding of isoketals to ethanolamine phospholipids. Free Radic. Biol. Med. 37 (2004) 1604-1611
27. Poliakov E., Brennan M.L., Macpherson J., Zhang R., Sha W., Narine L., Salomon R.G., and Hazen S.L. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J. 17 (2003) 2209-2220
28. Laird J.M. Isolevuglandin-derived hydroxylactams: total synthesis and generation of an isoLG-modified lysine. Chemistry (2007), Case Western Reserve Univ., Cleveland 22-47
29. Gu J., Paeur G.J., Yue X., Narendra U., Sturgill G.M., Bena J., Gu X., Peachey N.S., Salomon R.G., Hagstrom S.A., and Crabb J.W. Clinical Genomic and Proteomic AMD Study Group. Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol. Cell. Proteomics 8 (2009) 1338-1349
30. Gu X., Meer S.G., Miyagi M., Rayborn M.E., Hollyfield J.G., Crabb J.W., and Salomon R.G. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J. Biol. Chem. 278 (2003) 42027-42035
31. Podrez E.A., Poliakov E., Shen Z., Zhang R., Deng Y., Sun M., Finton P.J., Shan L., Febbraio M., Hajjar D.P., Silverstein R.L., Hoff H.F., Salomon R.G., and Hazen S.L. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277 (2002) 38517-38523
32. Podrez E.A., Schmitt D., Hoff H.F., and Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103 (1999) 1547-1560
33. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
34. Roychowdhury S., McMullen M.R., Pritchard M.T., Li W., Salomon R.G., and Nagy L.E. Formation of γ-ketoaldehyde-protein adducts during early stages of ethanol induced liver injury. Free Radic. Biol. Med. 47 (2009) 1526-1538
35. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
36. Murphy R.C., Barkley R.M., Zemski Berry K., Hankin J., Harrison K., Johnson C., Krank J., McAnoy A., Uhlson C., and Zarini S. Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal. Biochem. 346 (2005) 1-42
37. Lu Y., Hong S., Yang R., Uddin J., Gotlinger K.H., Petasis N.A., and Serhan C.N. Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. Rapid Commun. Mass. Spectrom. 21 (2007) 7-22
38. Brooks J.D., Milne G.L., Yin H., Sanchez S.C., Porter N.A., and Morrow J.D. Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem. 283 (2008) 12043-12055
39. Johnson E.J., and Schaefer E.J. Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. Am. J. Clin. Nutr. 83 (2006) 1494S-1498S
40. Giacometti J., Milosevic A., and Milin C. Gas chromatographic determination of fatty acids contained in different lipid classes after their separation by solid-phase extraction. J. Chromatogr. A 976 (2002) 47-54
41. Schwarzenbach G., and Irving H. Complexometric Titrations (1957), Interscience, New York
42. Davies S.S., Amarnath V., Brame C.J., Boutaud O., and Roberts II L.J. Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry. Nat. Protoc. 2 (2007) 2079-2091
43. Nagata K., Suzuki H., and Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 32 (2007) 453-468
44. Lumeng L., and Crabb D.W. Alcoholic liver disease. Curr. Opin. Gastroenterol. 16 (2000) 208-218
45. 2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J. Neurochem. 96 (2006) 917-923
46. Crabb J.W., Miyagi M., Gu X., Shadrach K., West K.A., Sakaguchi H., Kamei M., Hasan A., Yan L., Rayborn M.E., Salomon R.G., and Hollyfield J.G. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 99 (2002) 14682-14687
47. Ni J., Yuan X., Gu J., Yue X., Gu X., Nagaraj R.H., and Crabb J.W. Study Group, C. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol. Cell. Proteomics 8 (2009) 1921-1933
48. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., and Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retinal Eye Res. 20 (2001) 705-732
49. Scholl H.P., Charbel Issa P., Walier M., Janzer S., Pollok-Kopp B., Borncke F., Fritsche L.G., Chong N.V., Fimmers R., Wienker T., Holz F.G., Weber B.H., and Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS ONE 3 (2008) e2593
50. Edelstein C. General properties of plasma lipoproteins and apolipoproteins. In: Scanu A.M., and Spector A.A. (Eds). Biochemistry of Plasma Lipoproteins (1990), Dekker, New York 497
51. Heller J.I., Crowley J.R., Hazen S.L., Salvay D.M., Wagner P., Pennathur S., and Heinecke J.W. p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J. Biol. Chem. 275 (2000) 9957-9962
52. Zieseniss S., Zahler S., Muller I., Hermetter A., and Engelmann B. Modified phosphatidylethanolamine as the active component of oxidized low density lipoprotein promoting platelet prothrombinase activity. J. Biol. Chem. 276 (2001) 19828-19835
53. White D.A. The phospholipid composition of mammalian tissues. In: Ansell G.B., Hawthorne J.N., and Dawson R.M.C. (Eds). Form and Function of Phospholipids (1973), Elsevier, Amsterdam 441-482
54. de Kruijff B. Biomembranes: lipids beyond the bilayer. Nature 386 (1997) 129-130
55. 2. Prostaglandins Leukotrienes Essent. Fatty Acids 47 (1992) 105-110
56. Esterbauer H., Koller E., Slee R.G., and Koster J.F. Possible involvement of the lipid-peroxidation product 4-hydroxynonenal in the formation of fluorescent chromolipids. Biochem. J. 239 (1986) 405-409
57. Chen J.J., and Yu B.P. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radic. Biol. Med. 17 (1994) 411-418
58. 2 crosslinks proteins. Prostaglandins 37 (1989) 471-480
59. Jain S.K. The accumulation of malonyldialdehyde, a product of fatty acid peroxidation, can disturb aminophospholipid organization in the membrane bilayer of human erythrocytes. J. Biol. Chem. 259 (1984) 3391-3394